| Literature DB >> 31681526 |
Christoph Denk1, Martin Wilkovitsch1, Emma Aneheim2, Matthias M Herth3,4, Holger Jensen4, Sture Lindegren2, Hannes Mikula1.
Abstract
In the past decade, several developments have expanded the chemical toolbox for astatination and the preparation of 211At-labeled radiopharmaceuticals. However, there is still a need for advanced methods for the synthesis of astatinated (bio)molecules to address challenges such as limited in vivo stability. Herein, we report the development of multifunctional 211At-labeled reagents that can be prepared by applying a modular and versatile click approach for rapid assembly. The introduction of tetrazines as bioorthogonal tags enables rapid radiolabeling and radio-crosslinking, which is demonstrated by steric shielding of 211At to significantly increase label stability in human blood plasma.Entities:
Keywords: bioorthogonal chemistry; click chemistry; multicomponent reactions; radiochemistry; radiolabeling
Mesh:
Substances:
Year: 2019 PMID: 31681526 PMCID: PMC6813637 DOI: 10.1002/cplu.201900114
Source DB: PubMed Journal: Chempluschem ISSN: 2192-6506 Impact factor: 2.863
Figure 1Rapid assembly of multifunctional 211At‐reagents applicable for rapid bioorthogonal radiolabeling, crosslinking and/or steric shielding to increase label stability.
Figure 2(a) Rapid and modular assembly of 211At‐labeled compounds applying a three‐component copper‐catalyzed click reaction. (b) The radiochemical yield of click‐astatination depends on reaction time and temperature as shown for the synthesis of 1. (c) Synthesized 211At‐labeled compounds 1–12 including methyl‐substituted tetrazines, more reactive H‐tetrazines and the two multifunctional biotinylated 211At‐tetrazines 8 and 12. (d) Radiochemical yields of compounds 1–12 (10 min reaction time, 60 °C, 2.4–2.6 MBq 211At) as determined by radio‐HPLC (see Supporting Information; n=1).
Figure 3(a) Structure Verification of 211At‐labeled compounds using multifunctional compound 12, non‐reactive compound 3 as a control, and functionalized magnetic beads. (b) Compound 12 was reacted with either TCO‐ or streptavidin‐functionalized beads and radioactivity was measured after magnetic separation. (c) Both Tz‐driven removal of 12 based on bioorthogonal ligation to TCO‐beads and biotin‐driven removal by binding to streptavidin‐beads was shown (in comparison to control experiments using compound 3 to correct for unspecific binding to the beads).
Figure 4Radio‐crosslinking using the biotinylated 211At‐tetrazine 12. (a) TCO‐beads were reacted with 12 by bioorthogonal Tz ligation followed by shielding with streptavidin. (b) In an analogous experiment, streptavidin‐functionalized beads were radio‐crosslinked with 12 to TCO‐PEG(2k). (c) Steric shielding of 12 (on beads) with either streptavidin or TCO‐PEG(2k) was shown to significantly reduce degradation/deastatination and thus increase label stability (up to >10‐fold) in human blood plasma (incubation time of 5 hours) in comparison to unshielded 12 on beads as a control.